Strategies in Patients with Other Molecular Alterations

摘要: The paradigm of lung cancer treatment has rapidly changed in the last 10 years thanks to introduction molecularly tailored drugs, especially for adenocarcinoma. After successes obtained with target agents EGFR mutation and ALK rearrangement positive patients, a number new molecular markers have been identified, such as HER2 aberrations, MET FGFR1 amplification, BRAF DDR2 mutations, others. A driver may be identified up 60 % adenocarcinoma, whereas biological knowledge squamous cell carcinoma is at an earlier stage targetable alteration found only 30 cases. Most changes display low frequency (<5 %) but represent appealing actionable targets therapy. Drugs already approved use other tumors novel are currently being explored selected subcategories cancer, neratinib mutated patients or dabrafenib subjects bearing mutation. Initial results clinical studies reports promising allow envision brighter future research cancer.